Technical Analysis for BIT - Biotron Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.070 | -1.41% | -0.001 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Boomer Buy Setup | Bullish Swing Setup | -1.41% | |
| NR7 | Range Contraction | -1.41% | |
| Narrow Range Bar | Range Contraction | -1.41% | |
| Oversold Stochastic | Weakness | -1.41% | |
| Fell Below 200 DMA | Bearish | -1.41% | |
| Narrow Range Bar | Range Contraction | -1.41% | |
| Down 3 Days in a Row | Weakness | -1.41% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 1 day ago |
| Outside Day | 1 day ago |
| Down 1% | 1 day ago |
| 200 DMA Resistance | 1 day ago |
| Boomer Buy Entry | 1 day ago |
Get this analysis on your stocks daily!
Biotron Limited Description
Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Media Biotechnology Drugs Flu Clinical Trial Protein Microbiology Hepatitis Siding Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.125 |
| 52 Week Low | 0.024 |
| Average Volume | 2,324,099 |
| 200-Day Moving Average | 0.072 |
| 50-Day Moving Average | 0.079 |
| 20-Day Moving Average | 0.075 |
| 10-Day Moving Average | 0.074 |
| Average True Range | 0.005 |
| RSI (14) | 33.77 |
| ADX | 37.78 |
| +DI | 37.838 |
| -DI | 18.378 |
| Chandelier Exit (Long, 3 ATRs) | 0.094 |
| Chandelier Exit (Short, 3 ATRs) | 0.084 |
| Upper Bollinger Bands | 0.083 |
| Lower Bollinger Band | 0.067 |
| Percent B (%b) | 0.19 |
| BandWidth | 20.856 |
| MACD Line | -0.002 |
| MACD Signal Line | -0.001 |
| MACD Histogram | -0.0004 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.075 | ||||
| Resistance 3 (R3) | 0.075 | 0.074 | 0.074 | ||
| Resistance 2 (R2) | 0.074 | 0.073 | 0.074 | 0.073 | |
| Resistance 1 (R1) | 0.072 | 0.072 | 0.072 | 0.072 | 0.073 |
| Pivot Point | 0.071 | 0.071 | 0.071 | 0.071 | 0.071 |
| Support 1 (S1) | 0.069 | 0.070 | 0.069 | 0.069 | 0.067 |
| Support 2 (S2) | 0.068 | 0.069 | 0.068 | 0.067 | |
| Support 3 (S3) | 0.066 | 0.068 | 0.066 | ||
| Support 4 (S4) | 0.066 |
